Erasca, Inc. (ERAS)
14.41
+1.14
(+8.59%)
USD |
NASDAQ |
Nov 06, 16:00
14.52
+0.11
(+0.76%)
After-Hours: 20:00
Erasca Cash from Operations (Quarterly) : -27.27M for June 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -27.27M |
| March 31, 2026 | -27.38M |
| December 31, 2025 | -21.71M |
| September 30, 2025 | -21.66M |
| June 30, 2025 | -20.53M |
| March 31, 2025 | -31.56M |
| December 31, 2024 | -24.56M |
| September 30, 2024 | -22.42M |
| June 30, 2024 | -29.18M |
| March 31, 2024 | -33.25M |
| December 31, 2023 | -24.79M |
| September 30, 2023 | -24.12M |
| June 30, 2023 | -25.95M |
| Date | Value |
|---|---|
| March 31, 2023 | -26.36M |
| December 31, 2022 | -26.37M |
| September 30, 2022 | -23.94M |
| June 30, 2022 | -27.14M |
| March 31, 2022 | -25.81M |
| December 31, 2021 | -22.48M |
| September 30, 2021 | -23.22M |
| June 30, 2021 | -18.23M |
| March 31, 2021 | -15.67M |
| December 31, 2020 | -13.10M |
| September 30, 2020 | -7.476M |
| June 30, 2020 | -6.505M |
| March 31, 2020 | -5.61M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -177.47M |
| Twist Bioscience Corp. | 1.115M |
| Immunome, Inc. | -61.69M |
| Oncolytics Biotech, Inc. | -8.066M |
| Sangamo Therapeutics, Inc. | -19.28M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 19.49M |
| Cash from Financing (Quarterly) | 3.064M |
| Free Cash Flow | -98.08M |
| Free Cash Flow Per Share (Quarterly) | -0.0876 |
| Free Cash Flow to Equity (Quarterly) | -26.04M |
| Free Cash Flow to Firm (Quarterly) | -27.28M |
| Free Cash Flow Yield | -2.30% |